GlassScriptPhysician profile
Teresa E Kirisits
NPI 1619485786
$15,275.57
in general payments reported to CMS, 2019-2025
31 companies · $2,977 in 2025
The $2,977 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,235 · 2022: $1,611 · 2023: $2,304 · 2024: $7,149 · 2025: $2,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,619 · Consulting Fee: $2,150 · Travel and Lodging: $1,264 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,619.27 |
| Consulting Fee | $2,150.00 |
| Travel and Lodging | $1,264.39 |
| Education | $395.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $4,653.13 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $2,065.37 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $1,631.11 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,345.85 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,110.98 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,004.92 | 2022-2025 | Sunosi, Auvelity |
| Otsuka America Pharmaceutical, INC. | $542.67 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Novo Nordisk INC | $442.98 | 2021-2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $296.59 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $278.27 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $265.41 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.45 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $244.08 | 2021-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $205.52 | 2021-2024 | Ingrezza, Ongentys |
| Corium, LLC | $147.27 | 2022-2023 | Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $143.35 | 2022-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $137.37 | 2024-2025 | Spravato |
| Eisai INC. | $95.34 | 2021 | |
| Emd Serono, INC. | $80.73 | 2024 | Mavenclad |
| Amgen INC. | $53.23 | 2021-2022 | |
| Resmed Corp | $46.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $39.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.84 | 2025 | Trintellix |
| Noven Therapeutics, LLC | $23.55 | 2024 | Xelstrym |
| Ucb, INC. | $23.17 | 2022 | |
| Indivior INC. | $22.06 | 2025 | Sublocade |
| Owp Pharmaceuticals, INC. | $20.56 | 2025 | Subvenite |
| Inspire Medical Systems, INC. | $18.06 | 2023 | Inspire |
| Lundbeck LLC | $17.10 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $16.57 | 2023 | Daybue |
| Braeburn INC. | $15.82 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Kirisits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.